Phase IIb, Randomized Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer (GRECO-2)
Summary
The purpose of this phase IIb, multicenter, randomized, double-blind, placebo-controlled study is to determine the effect on overall survival by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic pancreatic cancer.
General Information
NCT#: NCT04698915
Study ID: GTI-4711-201
Trial Phase: Phase II
Trial Sponsor: Galera Therapeutics, Inc.
Therapies Used in This Trial: Stereotactic body radiotherapy (SBRT), GC4711